Edition:
United States

MediciNova Inc (MNOV.A)

MNOV.A on American Stock Exchange

5.66USD
4:00pm EDT
Change (% chg)

$0.19 (+3.47%)
Prev Close
$5.47
Open
--
Day's High
$5.66
Day's Low
$5.66
Volume
0
Avg. Vol
--
52-wk High
$5.66
52-wk Low
$4.41

Latest Key Developments (Source: Significant Developments)

MediciNova Inc announces interim data from clinical trial of MN-166 (ibudilast) in ALS
Wednesday, 20 Apr 2016 06:00am EDT 

MediciNova Inc:Announces interim data from clinical trial of MN-166 in ALS presented at the American Academy of Neurology 68th annual meeting in Vancouver, Canada.No cluster of adverse events was differentially present in MN-166 treatment and placebo treatment subjects.  Full Article

MediciNova Inc announces Ryan Selhorn as new CFO
Thursday, 31 Mar 2016 06:30am EDT 

MediciNova Inc:Appoints Ryan Selhorn as new CFO effective March 31.  Full Article

MediciNova Inc receives notice of allowance for new patent covering MN-001 in China
Sunday, 27 Mar 2016 07:00pm EDT 

MediciNova Inc:Says it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 (tipelukast).Says the allowed claims cover the compound as a polymorphic form of MN-001 (tipelukast), pharmaceutical compositions, and manufacturing processes.Says the allowed claims cover oral administration including tablets and capsule.  Full Article

MediciNova Inc Receives Notice of Allowance for New Patent Covering MN-001 and MN-002
Wednesday, 23 Mar 2016 07:00pm EDT 

MediciNova Inc:Says it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.  Full Article

MediciNova Inc receives fast track designated approval from FDA for MN-166
Tuesday, 22 Mar 2016 06:00am EDT 

MediciNova Inc:Receives FDA fast track designated approval for MN-166 for the treatment of progressive multiple sclerosis.  Full Article

MediciNova Inc receives patent for MN-166 in U.S.
Monday, 7 Mar 2016 06:00pm EST 

MediciNova Inc:Receives a patent for MN-166 (for amyotrophic lateral sclerosis (ALS) treatment) in U.S., with valid as of July 2028.  Full Article

MediciNova Inc announces positive result of phase II clinical trials of MN-166
Sunday, 6 Mar 2016 06:00pm EST 

MediciNova Inc:Announces positive result of the phase II clinical trial for MN-166 (for Opioid Use Disorder treatment) in the United States on March 5.  Full Article

MediciNova Inc Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
Wednesday, 27 Jan 2016 06:00pm EST 

MediciNova Inc:Says it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced NASH (nonalcoholic steatohepatitis) with fibrosis.Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than September 2034.The allowed claims cover a method of treating advanced NASH with fibrosis, a method of reducing hepatic fibrosis in advanced NASH, and a method of reducing hepatic scarring in advanced NASH using MN-001 or MN-002.The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.  Full Article

MediciNova Inc receives notice of allowance for new patent covering MN-029 (denibulin) di-hydrochloride in Europe
Wednesday, 13 Jan 2016 06:00pm EST 

MediciNova Inc:Announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.Says the allowed claims cover the compound, pharmaceutical compositions and a method of treating certain cell proliferative diseases, including cancer, using MN-029 (denibulin) di-hydrochloride.  Full Article

MediciNova Inc receives patent in China
Monday, 14 Dec 2015 06:00pm EST 

MediciNova Inc:Receives a patent for MN-029-2HCL in China, with valid until July 2032.  Full Article

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence